The Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B pipeline drugs market research report outlays comprehensive information on the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Oncology, Metabolic Disorders, Central Nervous System, and Gastrointestinal which include the indications Colorectal Cancer, Non-Small Cell Lung Cancer, Obesity, Type 1 Diabetes (Juvenile Diabetes), Alzheimer’s Disease, Tauopathies, and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). It also reviews key players involved in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B targeted therapeutics development with respective active and dormant or discontinued products.

The Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B pipeline targets constitutes close to nine molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 1, 7, and 1 respectively.

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B overview

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B is an enzyme that in humans is encoded by a gene DYRK1B. It belongs to a family of nuclear-localized protein kinases and possesses both serine/threonine and tyrosine kinase activities. The encoded protein participates in the regulation of the cell cycle. Expression of this gene may be altered in tumor cells, and mutations in this gene were found to cause abdominal obesity-metabolic syndrome 3.

For a complete picture of Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.